Literature DB >> 11304724

Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression.

M M Webber1, S T Quader, H K Kleinman, D Bello-DeOcampo, P D Storto, G Bice, W DeMendonca-Calaca, D E Williams.   

Abstract

BACKGROUND: The study of prostate carcinogenesis and tumor progression is made difficult by the lack of appropriate in vitro and in vivo models. High prevalence of prostatic intra-epithelial neoplasia and latent prostatic carcinoma, representing multiple steps in carcinogenesis to invasive carcinoma, are relevant targets for cancer prevention. From the RWPE-1, immortalized, non-tumorigenic, human prostate epithelial cell line, we have derived four tumorigenic cell lines with progressive malignant characteristics.
METHODS: Cell lines were derived by exposure of RWPE-1 to N-methyl-N-nitrosourea (MNU), selected and cloned in vivo and in vitro, and characterized by prostatic epithelial and differentiation markers, karyotype analysis, anchorage-independent growth, invasiveness, tumorigenicity, and pathology of the derived tumors.
RESULTS: Cytokeratins 8 and 18, androgen receptor, and prostate-specific antigen expression in response to androgen, confirm prostatic epithelial origin. RWPE-1 cells do not grow in agar and are not tumorigenic in mice, but the growth, tumorigenicity, and tumor pathology of the MNU cell lines correlate with their invasive ability. The WPE1-NA22 (least malignant) form small, well-differentiated, and WPE1-NB26 cells (most malignant) form large, poorly differentiated, invasive tumors. Overall, loss of heterozygosity for chromosomes 7q, 13q, 18q, and 22, and gain of 5, 9q, 11q, and 20, was observed. The MNU cell lines, in order of increasing malignancy are; WPE1-NA22, WPE1-NB14, WPE1-NB11, and WPE1-NB26.
CONCLUSIONS: This family of cell lines with a common lineage represents a unique and relevant model which mimics stages in prostatic intra-epithelial neoplasia (PIN) and progression to invasive cancer, and can be used to study carcinogenesis, progression, intervention, and chemoprevention.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11304724     DOI: 10.1002/pros.1041

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  39 in total

1.  Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells.

Authors:  Erik J Tokar; Mukta M Webber
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

2.  Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells.

Authors:  Erik J Tokar; Mukta M Webber
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  Arsenic-specific stem cell selection during malignant transformation.

Authors:  Erik J Tokar; Wei Qu; Jie Liu; Wei Liu; Mukta M Webber; James M Phang; Michael P Waalkes
Journal:  J Natl Cancer Inst       Date:  2010-03-25       Impact factor: 13.506

4.  Differentiation of prostate epithelial cell cultures by matrigel/ stromal cell glandular reconstruction.

Authors:  Shona H Lang; Joel Smith; Catherine Hyde; Catherine Macintosh; Michael Stower; Norman J Maitland
Journal:  In Vitro Cell Dev Biol Anim       Date:  2006 Sep-Oct       Impact factor: 2.416

5.  The amyloid precursor protein/protease nexin 2 Kunitz inhibitor domain is a highly specific substrate of mesotrypsin.

Authors:  Moh'd A Salameh; Jessica L Robinson; Duraiswamy Navaneetham; Dipali Sinha; Benjamin J Madden; Peter N Walsh; Evette S Radisky
Journal:  J Biol Chem       Date:  2009-11-17       Impact factor: 5.157

6.  Growth inhibition mediated by PSP94 or CRISP-3 is prostate cancer cell line specific.

Authors:  Bhakti R Pathak; Ananya A Breed; Vaishali H Nakhawa; Dhanashree D Jagtap; Smita D Mahale
Journal:  Asian J Androl       Date:  2010-08-02       Impact factor: 3.285

7.  Differential DNA methylation profile of key genes in malignant prostate epithelial cells transformed by inorganic arsenic or cadmium.

Authors:  Katherine E Pelch; Erik J Tokar; B Alex Merrick; Michael P Waalkes
Journal:  Toxicol Appl Pharmacol       Date:  2015-04-25       Impact factor: 4.219

8.  PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer.

Authors:  Alexandra Hockla; Erin Miller; Moh'd A Salameh; John A Copland; Derek C Radisky; Evette S Radisky
Journal:  Mol Cancer Res       Date:  2012-12       Impact factor: 5.852

Review 9.  Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management.

Authors:  Vaqar Mustafa Adhami; Deeba Nadeem Syed; Naghma Khan; Hasan Mukhtar
Journal:  Biochem Pharmacol       Date:  2012-07-25       Impact factor: 5.858

Review 10.  Chemoprevention of carcinoma prostate: a review.

Authors:  M S Ansari; N P Gupta; A K Hemal
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.